Photo by Robert Hood / Fred Hutch file
In a report to the White House released today, an independent advisory group called for “urgent action” to address rapidly rising prices for cancer drugs and the burden cancer patients and their families can face because of the high cost of cancer care.
It issued six recommendations to ensure alignment of drug prices with their value, promote use of high-value drugs, and support innovation in cancer drug development.
Dr. Gary Gilliland, president and director of Fred Hutchinson Cancer Research Center, participated in workshops that led to the drafting of the report, and applauded the panel’s efforts to keep the needs of patients as its central focus.
“We're not just racing to find cures, we're racing to find ways to lower the cost of cures, and support innovative ideas like value-based pricing to make health care more affordable to all," said Gilliland.
The report, “Promoting Value, Affordability, and Innovation in Cancer Drug Treatment,” is the latest released by the advisory group, called the President’s Cancer Panel, which since 1971 has regularly provided U.S. presidents a report on high-priority issues in the nation’s anti-cancer efforts.
Photo by Al Drago for Fred Hutch News Service
It declared that all patients should have affordable access to appropriate drugs, but also underscored that sustained funding for cancer research and partnerships between private biomedical firms and non-profit research institutions are essential.
The report cited a survey by the American Society of Clinical Oncology that found 90 percent of Americans say cancer drugs are too costly. New cancer drugs are entering the market priced at well over $100,000, and the prices of many existing drugs have risen dramatically in recent years, putting patients at risk of “financial toxicity.”
Former Seattle resident Erin Havel is one of them. Diagnosed with chronic myeloid leukemia in 2007, she benefited from the precision oncology drug Gleevec. But as the price of Gleevec climbed — from $26,000 a year when it was approved in 2001 to $146,000 by 2016 — Havel struggled to pay for treatment and basic necessities like groceries, eventually filing for bankruptcy.
Financial toxicity is a major concern and frequent topic of study by the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch. HICOR director Dr. Scott Ramsey, a health economist, is a proponent of value-based pricing and contributed his expertise to the panel report.
Learn more about the cost of cancer care, value-based pricing and financial toxicity
Drug pricing should depend on shared values
Nature | Dr. Scott Ramsey | Dec. 20, 2017
Financial toxicity: 1 in 3 cancer patients have to turn to friends or family to pay for care
STAT News First Opinion | Drs. Scott Ramsey and Veena Shankaran | Nov. 2, 2016
'Close to criminal': Oncologist speaks out on the human toll of high health care costs
Hutch News | Dr. Gary Lyman | Feb. 11, 2016
Related Fred Hutch research
Cancer, bankruptcy and death: study finds a link
Jan. 25, 2016
Cruel choices: Buy lifesaving meds or grocieries?
June 3, 2015
Sabin Russell is a staff writer at Fred Hutchinson Cancer Research Center. For two decades he covered medical science, global health and health care economics for the San Francisco Chronicle, and wrote extensively about infectious diseases, including HIV/AIDS. He was a Knight Science Journalism Fellow at MIT, and a freelance writer for the New York Times and Health Affairs. Reach him at email@example.com.
Are you interested in reprinting or republishing this story? Be our guest! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email us at firstname.lastname@example.org